If the positive short-term effects of SGLT-2 inhibitors, along with their favorable pharmacodynamics, are confirmed in AF models, this could encourage further investigation into their use as adjunctive therapy in clinical trials related to paroxysmal AF. The gene discussed is SLC5A2; the disease is Paroxysmal atrial fibrillation.